IRIS
ROTI, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.290
AS - Asia 3.760
EU - Europa 3.189
SA - Sud America 616
AF - Africa 200
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 12.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.164
SG - Singapore 1.642
CN - Cina 1.141
IT - Italia 935
IE - Irlanda 490
BR - Brasile 489
SE - Svezia 359
HK - Hong Kong 356
DE - Germania 330
VN - Vietnam 231
FI - Finlandia 187
NL - Olanda 179
UA - Ucraina 148
ZA - Sudafrica 129
GB - Regno Unito 106
FR - Francia 105
AT - Austria 101
RU - Federazione Russa 101
TR - Turchia 94
CA - Canada 75
IN - India 72
AR - Argentina 50
BD - Bangladesh 49
MX - Messico 33
CI - Costa d'Avorio 31
JP - Giappone 31
PL - Polonia 30
IQ - Iraq 25
BE - Belgio 24
EC - Ecuador 22
KR - Corea 22
ES - Italia 17
CZ - Repubblica Ceca 16
ID - Indonesia 16
CO - Colombia 15
LT - Lituania 13
IR - Iran 12
PY - Paraguay 10
VE - Venezuela 10
PK - Pakistan 9
UZ - Uzbekistan 8
AU - Australia 7
CL - Cile 7
DZ - Algeria 7
EG - Egitto 7
UY - Uruguay 7
IL - Israele 6
JM - Giamaica 6
KE - Kenya 6
MA - Marocco 6
PA - Panama 6
RO - Romania 6
TN - Tunisia 6
AZ - Azerbaigian 5
CH - Svizzera 5
LU - Lussemburgo 5
BG - Bulgaria 4
ET - Etiopia 4
HU - Ungheria 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NP - Nepal 4
PE - Perù 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
DO - Repubblica Dominicana 3
GR - Grecia 3
HR - Croazia 3
LB - Libano 3
OM - Oman 3
PH - Filippine 3
RS - Serbia 3
TH - Thailandia 3
BH - Bahrain 2
KH - Cambogia 2
MD - Moldavia 2
MY - Malesia 2
NO - Norvegia 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
BO - Bolivia 1
BY - Bielorussia 1
CD - Congo 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
EE - Estonia 1
EU - Europa 1
GP - Guadalupe 1
KW - Kuwait 1
LK - Sri Lanka 1
LV - Lettonia 1
MT - Malta 1
NG - Nigeria 1
NR - Nauru 1
SK - Slovacchia (Repubblica Slovacca) 1
SR - Suriname 1
Totale 12.064
Salva come PNG Salva come JPEG
Città #
Singapore 879
Ashburn 625
Dublin 490
Chandler 472
Dallas 472
Hong Kong 352
Beijing 279
Parma 274
Santa Clara 263
Boardman 220
Jacksonville 135
Ann Arbor 126
Johannesburg 123
Dearborn 105
Munich 99
Los Angeles 93
Princeton 90
Vienna 86
Nanjing 85
New York 84
Ho Chi Minh City 83
Shanghai 79
Izmir 72
Hefei 70
Bologna 62
Milan 62
Wilmington 62
Helsinki 55
Grafing 53
Shenyang 51
San Mateo 50
São Paulo 50
Hanoi 49
Marseille 48
Jinan 44
Nanchang 43
Moscow 42
Columbus 37
Buffalo 35
Toronto 35
Hebei 32
Turku 32
Abidjan 31
Seattle 31
Rome 30
Guangzhou 27
Amsterdam 26
Changsha 25
Montreal 25
Tianjin 25
Modena 24
Verona 24
Nuremberg 23
The Dalles 23
Tokyo 23
Chicago 22
Kunming 22
Reggio Emilia 22
Seoul 22
Brussels 21
Des Moines 21
Warsaw 21
Rio de Janeiro 20
Frankfurt am Main 19
Pune 19
Bremen 17
Brooklyn 17
Denver 17
London 17
Poplar 17
Brescia 16
Fremont 16
Houston 16
Jiaxing 16
Da Nang 15
Phoenix 15
West Jordan 14
Atlanta 13
Brasília 13
Jakarta 13
Norwalk 13
Perugia 13
Zhengzhou 13
Brno 12
Düsseldorf 12
Haiphong 12
San Francisco 12
Belo Horizonte 11
Bengaluru 11
Quattro Castella 11
Woodbridge 11
Chongqing 10
Council Bluffs 10
Florence 10
Hangzhou 10
Manchester 10
Mexico City 10
Quito 10
San Jose 10
Baghdad 9
Totale 7.496
Salva come PNG Salva come JPEG
Nome #
Blockade of Oncogenic NOTCH1 with the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 217
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 197
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients 181
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 177
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 176
227P Sexual dimorphism in immune profile of early and advanced NSCLC 173
Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia 172
Targeting oncogenic Notch signaling with SERCA inhibitors 165
Morphological, clinical, and molecular profiling of post-polycythemia vera accelerated/blast phase occurring with and without antecedent secondary myelofibrosis 160
Impact of the rs1024611 polymorphism of ccl2 on the pathophysiology and outcome of primary myelofibrosis 160
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia 159
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 147
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 144
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 139
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 139
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 137
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 136
Bone marrow endothelial cells carry bcr/abl fusion gene from chronic myeloid leukemia patients 136
Angiopoietins expression by human myeloma cells 135
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 134
Dataset on the identification of a prognostic radio-immune signature in surgically resected Non Small Cell Lung Cancer 132
IL-7 is induced by IL-6 in human myeloma cells: role in multiple myeloma 131
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 129
Hematologic malignancies with extramedullary spread of disease. Case 1. Multiple myeloma with extramedullary involvement of the pleura and testes 128
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 126
Human myeloma cells produce angiopoietin-1 but not angiopoietin-2: potential relationship with myeloma-induced angiogenesis 125
Identification of the Atypical Protein Kinase WNK1 As a New Target in T-Cell Acute Lymphoblastic Leukemia 119
Acute lymphoblastic leukaemia in Noonan syndrome. 118
Targeting Notch Trafficking and Processing in Cancers 118
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC 116
BCR/ABL fusion gene is detected in chronic myeloid leukemia endothelial cells 115
Down-Modulation of Erk Protein Kinase Activity Inhibits Vascular Endothelial Growth Factor (VEGF) Secretion by human Myeloma Cell Lines 110
Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors 109
Activating somatic and germline TERT promoter variants in myeloid malignancies 108
THERAPEUTIC TARGETING OF NOTCH SIGNALING PATHWAY IN HEMATOLOGICAL MALIGNANCIES 108
Orthogonal Proteogenomic Approaches Identify the Druggable PA2G4-MYC Axis in 3q26 AML 108
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 107
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 107
VASCULAR ENDOTHELIAL GROWTH FACTOR SECRETION BY MYELOMA CELLS IS INHIBITED BY DOWN-MODULATING ERK PROTEIN KINASE ACTIVITY 106
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia 106
Venetoclax and bortezomib in relapsed/refractory early t-cell precursor acute lymphoblastic leukemia 106
Osteopontin is produced by human multiple myeloma cells 105
Multiple myeloma patient with unusual extramedullary involvement 105
SERCA MODULATION COUNTERACTS GLUCOCORTICOID RESISTANCE IN T-ALL 104
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 104
IL-7 is produced by myeloma cells in presence of IL-6 104
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia 104
CAD204520 Targets NOTCH1 PEST Domain Mutations in Lymphoproliferative Disorders 103
Human myeloma cells production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis 102
Haploidentical hematopoietic stem cell transplantation in adults using the αβTCR/CD19-based depletion of G-CSF-mobilized peripheral blood progenitor cells 100
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 99
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL 99
Down-modulation of ERK protein kinase activity suppresses human myeloma cell proliferation and myeloma-induced angiogenesis by VEGF inhibition 98
Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro 97
Acute lymphoblastic leukaemia 97
The Atypical Protein Kinase WNK1 Controls Leukemia Progression in TAL/LMO T-Cell Acute Lymphoblastic Leukemia 95
Multiple Myeloma patient with unusual extramedullary involvement 95
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 95
Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling 95
Multiple myeloma patient with unusual extramedullary involvement 93
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines 92
A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome 91
SELECTIVE BLOCKADE OF ONCOGENIC NOTCH1 WITH THE NEW SERCA INHIBITOR CAD204520 90
Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T-cell lymphoblastic leukemia 90
Human myeloma cells express IL-7 mRNA and secrete IL-7 in presence of IL-6 90
WO/2016/073708 90
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 90
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML 89
Genetic and proteomic approaches to identify cancer drug targets. 89
Synergistic drug combinations with a CDK4/6 inhibitor in T-cell acute lymphoblastic leukemia 89
Paracrine rather than autocrine basic FGF (bFGF) loop in multiple myeloma 88
Bone marrow endothelial cells carry BCR/ABL fusion gene from chronic myeloid leukemia patients. 88
Cryptic chromosome 9q34 deletion generates TAF-Ialpha/CAN and TAF-Ibeta/CAN fusion transcripts in acute myeloid leukemia. 88
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes 88
Design of a Comprehensive Fluorescence in Situ Hybridization Assay for Genetic Classification of T-Cell Acute Lymphoblastic Leukemia 88
Bilateral tonsillar infiltration of T-cell prolymphocytic leukemia 87
Leukemia-specific delivery of mutant NOT CH1 targeted therapy 86
Nivolumab-Induced Guillain-Barré Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma 86
IL-7 is produced by myeloma cells in presence of IL-6 86
Selective Blockade of Oncogenic NOTCH1 with the New SERCA Inhibitor CAD204520 in T-cell Acute Lymphoblastic Leukemia 85
Genetics of Darier’s Disease: New Insights into Pathogenic Mechanisms 84
Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC 82
Genetic profile of acute lymphoblastic leukemia in a patient with the noonan syndrome 82
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. 78
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. 78
Modern treatment approaches to adult acute T-lymphoblastic and myeloid/T-lymphoblastic leukemia: From current standards to precision medicine 76
Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. 76
Differentially regulated high-throughput CT imaging features correlate to distinct tumor immune contextures portraying a radiomic signature with prognostic impact on surgically resected NSCLC 75
Down-modulation of ERK protein kinase activity inhibits vascular endothelial growth factor (VEGF) secretion by human myeloma cell lines. 74
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia 74
Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy with Thyroid Carcinoma Cells: Novel Translational Insights 74
Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. 73
Constitutive phosphorylation of Janus kinase2 in the GL15 glioblastoma derived human cell line 71
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 70
T(10;11)(P13;P14-21) PICALM-MLLT10 ACUTE LEUKEMIA: CHARACTERIZATION OF TWO CASES WITH DIFFERENT PHENOTYPIC PRESENTATION 69
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma 68
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma 68
FROM GENOMICS TO CHEMOGEGNOMICS IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA 67
Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAFV600E 67
DHPLC analysis of NPM1 mutations in adult primary AML. 65
Totale 10.751
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.060
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.060
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021352 0 0 0 0 0 17 34 23 128 47 78 25
2021/2022517 16 16 11 15 7 64 72 55 27 40 32 162
2022/20231.922 219 191 106 124 206 206 32 117 585 7 82 47
2023/2024987 50 64 29 41 85 184 124 80 40 72 72 146
2024/20253.056 90 164 215 235 337 246 145 137 350 251 275 611
2025/20264.020 582 537 1.006 669 936 290 0 0 0 0 0 0
Totale 12.263